- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
SUPPORT PHILSTAR
About Us |
Contact Us |
Advertise |
Privacy Policy |
Member Agreement |
Copyright Notice
Copyright © 2024. Philstar Global Corp. All Rights Reserved
X
+ Follow PEGINTERFERON Tag
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 687129 [Title] => Roche partners with Merck vs chronic hepatitis C [Summary] =>Roche has announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States.
[DatePublished] => 2011-05-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 16664 [Title] => Tolerability key to success of hepatitis C treatment [Summary] => [DatePublished] => 2007-09-27 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 300282 [Title] => New hepa B treatment outdoes standard care [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care.
A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.
[DatePublished] => 2005-10-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 274759 [Title] => New hepa B treatment cited [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited.
Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.
The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B.
[DatePublished] => 2005-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
PEGINTERFERON
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 687129 [Title] => Roche partners with Merck vs chronic hepatitis C [Summary] =>Roche has announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States.
[DatePublished] => 2011-05-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 16664 [Title] => Tolerability key to success of hepatitis C treatment [Summary] => [DatePublished] => 2007-09-27 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 300282 [Title] => New hepa B treatment outdoes standard care [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care.
A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.
[DatePublished] => 2005-10-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 274759 [Title] => New hepa B treatment cited [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited.
Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.
The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B.
[DatePublished] => 2005-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
May 19, 2011 - 12:00am
October 6, 2005 - 12:00am
April 21, 2005 - 12:00am
Recommended
The Insurance Commission has placed health maintenance organization Stotsenberg Healthcare Systems Inc.under conservatorship amid its inability to address requirements from the government.
1 day ago
Lotto Sep 19, 2024
EZ2 - 12 21
SUERTRES - 2 1 3
6D Lotto - 7 5 9 3 0 1
6/42 Lotto - 5 26 2 21 8 27
P19,033,913.00
6/49 Super Lotto - 32n 24 38 35 15
P62,95,035.00
Forex
February 12, 2018
- 12:00 am
- 12:00 am
1$ : P51.66